Log in to post a reply
Aug 2, 2016 04:01AM
Aug 2, 2016 04:28AM
Here is a Drug Bank paper on Chloroquine:
If chloroquine can stop the cells from metastasis, as it did it that mini-video, then maybe it can help people with breast cancer at any stage by making it impossible for the cancer to continue to move toward and infect or invade other cells. If it can't keep moving, growing and spreading, and if it can't copy itself or reproduce as it normally does, then it would would sit "stuck" and couldn't infect other cells. Chloroquine makes the cells more sensitive to chemo and radiation. Maybe Plaquenil is not the same form of chloroquine that scientists are using or maybe they are combining chloroquine with other drugs or enzymes and it is the combination of drugs that is making cancer cells get "stuck"? Maybe it couldn't use self-cannibalism (autophagy) to keep the cancer organism thriving if it was sort of glued to one place and couldn't move around. Scientists are also working on ways to coax cancer cells out of the bone marrow so chemo and radiation can kill them. Apparently, they can hide out there and are somehow protected from chemo and radiation while hiding there.
Chloroquine: Mode of Action
Use of chloroquine to treat metabolic syndrome
If chloroquine is used to treat metabolic syndrome, then it must effect glucose and insulin levels in the blood. Doctor Otto Warburg said cancer uses glucose to thrive. (I was wrong when i wrote he knew much about cancer cells circa 1930/1931, he already knew in the early 1920's)
How cancer cells fuel their growth https://www.sciencedaily.com/releases/2016/03/1603...
Malaria medicine chloroquine inhibits tumor growth, metastases, study showshttps://www.sciencedaily.com/releases/2014/08/1408...
Someone already wrote about this, but I am including it here. A Doctor Pedersen, who studied what Doctor Warburg found, and his colleagues, used 3-bromopyruvate to eliminate cancer cells.
3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue."
Although the "Warburg effect", i.e., elevated glucose metabolism to lactic acid (glycolysis) even in the presence of oxygen, has been recognized as the most common biochemical phenotype of cancer for over 80 years, its biochemical and genetic basis remained unknown for over 50 years. Work focused on elucidating the underlying mechanism(s) of the "Warburg effect" commenced in the author's laboratory in 1969. By 1985 among the novel findings made two related most directly to the basis of the "Warburg effect", the first that the mitochondrial content of tumors exhibiting this phenotype is markedly decreased relative to the tissue of origin, and the second that such mitochondria have markedly elevated amounts of the enzyme hexokinase-2 (HK2) bound to their outer membrane. HK2 is the first of a number of enzymes in cancer cells involved in metabolizing the sugar glucose to lactic acid. At its mitochondrial location HK2 binds at/near the protein VDAC (voltage dependent anion channel), escapes inhibition by its product glucose-6-phosphate, and gains access to mitochondrial produced ATP. As shown by others, it also helps immortalize cancer cells, i.e., prevents cell death. Based on these studies, the author's laboratory commenced experiments to elucidate the gene basis for the overexpression of HK2 in cancer. These studies led to both the discovery of a unique HK2 promoter region markedly activated by both hypoxic conditions and moderately activated by several metabolites (e.g., glucose), Also discovered was the promoter's regulation by epigenetic events (i.e., methylation, demethylation). Finally, the author's laboratory turned to the most important objective. Could they selectively and completely destroy cancerous tumors in animals? This led to the discovery in an experiment conceived, designed, and conducted by Young Ko that the small molecule 3-bromopyruvate (3BP), the subject of this mini-review series, is an incredibly powerful and swift acting anticancer agent. Significantly, in subsequent experiments with rodents (19 animals with advanced cancer) Ko led a project in which 3BP was shown in a short treatment period to eradicate all (100%). Ko's and co-author's findings once published attracted global attention leading world-wide to many other studies and publications related to 3BP and its potent anti-cancer effect. This Issue of the Journal of Bioenergetics and Biomembranes (JOBB 44-1) captures only a sampling of research conducted to date on 3BP as an anticancer agent, and includes also a Case Report on the first human patient known to the author to be treated with specially formulated 3BP. Suffice it to say in this bottom line, "3BP, a small molecule, results in a remarkable therapeutic effect when it comes to treating cancers exhibiting a "Warburg effect". This includes most cancer types.
I think they had some trouble with 3-bromopyruvate being too toxic. Maybe they are working on ways around that.
Pyruvate is involved in that Warburg glucose to lactic acid fermentation.